Sign In
Buy TVGN
$9.06
+0.590 (+6.97%)
At Close: Jun 03, 2026
WARREN, N.J., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced that its artificial intelligence initiative, Tevogen.AI, is ex
Tevogen CEO Affirms Strong Growth, Capital Position, and AI Expansion in Letter to Stockholders
03:57pm, Friday, 01'st Aug 2025
WARREN, N.J., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today released a letter to stockholders.
Tevogen Bio to Accept $1 Million Additional Grant Funding for AI Expansion
03:30pm, Friday, 01'st Aug 2025
WARREN, N.J., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or the “Company) (Nasdaq: TVGN), today announced that it expects to receive $1 million in grant funding to ad
Tevogen Highlights 74% Insider Ownership, Reinforcing Long-Term Vision
12:41pm, Wednesday, 30'th Jul 2025
WARREN, N.J., July 30, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today highlighted the Company's significant insider ownership of outstanding
Tevogen.AI Applauds U.S. Government's AI Action Plan; Reaffirms Commitment to Accelerating AI Innovation in Healthcare
11:52am, Monday, 28'th Jul 2025
WARREN, N.J., July 28, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today welcomes the White House's release of “Winning the Race: America's AI
Tevogen.AI Receives International Patent Publication for AI Technology Predicting Immunologically Active Peptides
12:36pm, Friday, 18'th Jul 2025
WARREN, N.J., July 18, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) announced today that the International Bureau of the World Intellectual Proper
Tevogen Signs Letter of Intent for New In-House Cell Therapy Manufacturing Facility
09:15am, Thursday, 17'th Jul 2025
WARREN, N.J., July 17, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced the signing of a letter of intent to lease a 17,428-square-foo
Tevogen.AI Targets Faster Time-to-Market with AI-Powered Patient Matching Following PredicTcell™ Alpha Launch
11:57am, Wednesday, 16'th Jul 2025
WARREN, N.J., July 16, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced that following the completion and deployment of the alpha vers
WARREN, N.J., July 14, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced that its artificial intelligence initiative, Tevogen.AI, in
Tevogen's New Headquarters, Fully Funded by CEO, Centralizes R&D and AI Teams to Accelerate Innovation
03:13pm, Thursday, 10'th Jul 2025
WARREN, N.J., July 10, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced the completion and official opening of its fully functional, n
Tevogen CEO Contributes to Build-Out and First-Year Operations of New Headquarters
02:28pm, Monday, 30'th Jun 2025
WARREN, N.J., June 30, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced that founder and Chief Executive Officer, Ryan Saadi, M.D., M.
Tevogen Updates on Development of EBV-Specific T Cell Therapy with Support from AI-Powered Target Discovery
08:30am, Wednesday, 18'th Jun 2025
WARREN, N.J., June 18, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today provided an update on its ongoing development of a cytotoxic T lymphocyt
Tevogen Expands Headquarters Amid Growth of AI and Generics & Biosimilars Initiatives
09:00am, Monday, 09'th Jun 2025
R&D and cross-functional operations will be centralized in a single location to enhance collaboration and operational efficiency. Tevogen.AI, strengthened by its partnership with Microsoft, continues
WARREN, N.J., May 30, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today provided stockholders with a detailed overview of its artificial intelli
WARREN, N.J., May 23, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced a planned expansion of TVGN 489's target population to include
